Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

Fig. 4

Unchanged levels of soluble amyloid precursor protein α (sAPPα) and sAPPβ in the brain of APPSWE/PS1ΔE9 (APP/PS1) mice chronically treated with escitalopram. Levels of sAPPα and sAPPβ in the neocortex (a, c) and hippocampus (b, d) of APP/PS1 mice after escitalopram treatment were measured by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193